Schleyer E - Search Results

1

Oxaliplatin pharmacokinetics during a four-hour infusion.

Kern W, Braess J, Böttger B, Kaufmann CC, Hiddemann W, Schleyer E. Kern W, et al. Among authors: schleyer e. Clin Cancer Res. 1999 Apr;5(4):761-5. Clin Cancer Res. 1999. PMID: 10213210 Clinical Trial.

2

Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.

Kern W, Braess J, Kotschofsky M, Samel S, Becker H, Hiddemann W, Schleyer E. Kern W, et al. Among authors: schleyer e. Anticancer Res. 2002 Sep-Oct;22(5):3099-102. Anticancer Res. 2002. PMID: 12530050 Clinical Trial.

3

Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve.

Kern W, Braess J, Friedrichsen S, Kaufmann CC, Schleyer E, Hiddemann W. Kern W, et al. Among authors: schleyer e. J Cancer Res Clin Oncol. 2001 Jan;127(1):64-8. doi: 10.1007/s004320000169. J Cancer Res Clin Oncol. 2001. PMID: 11206274

4

Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.

Kern W, Braess J, Kaufmann CC, Wilde S, Schleyer E, Hiddemann W. Kern W, et al. Among authors: schleyer e. Anticancer Res. 2000 Sep-Oct;20(5C):3679-88. Anticancer Res. 2000. PMID: 11268439 Clinical Trial.

5

Pharmacokinetics of Ara-CMP-Stearate (YNK01): phase I study of the oral Ara-C derivative.

Schleyer E, Braess J, Ramsauer B, Unterhalt M, Kaufmann C, Wilde S, Schüssler M, Hiddemann W. Schleyer E, et al. Leukemia. 1995 Jun;9(6):1085-90. Leukemia. 1995. PMID: 7596174 Clinical Trial.

6

New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites.

Schleyer E, Kamischke A, Kaufmann CC, Unterhalt M, Hiddemann W. Schleyer E, et al. Leukemia. 1994 Mar;8(3):435-40. Leukemia. 1994. PMID: 8127148

7

Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.

Schleyer E, Kühn S, Rührs H, Unterhalt M, Kaufmann CC, Kern W, Braess J, Sträubel G, Hiddemann W. Schleyer E, et al. Leukemia. 1996 Apr;10(4):707-12. Leukemia. 1996. PMID: 8618451 Clinical Trial.

8

High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.

Kern W, Schleyer E, Unterhalt M, Wörmann B, Büchner T, Hiddemann W. Kern W, et al. Among authors: schleyer e. Cancer. 1997 Jan 1;79(1):59-68. Cancer. 1997. PMID: 8988727

9

Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.

Schleyer E, Kühn S, Rührs H, Unterhalt M, Kaufmann CC, Kern W, Braess J, Sträubel G, Hiddemann W. Schleyer E, et al. Leukemia. 1997 Dec;11 Suppl 5:S15-21. Leukemia. 1997. PMID: 9436933

10

Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.

Braess J, Freund M, Hanauske A, Heil G, Kaufmann C, Kern W, Schüssler M, Hiddemann W, Schleyer E. Braess J, et al. Among authors: schleyer e. Leukemia. 1998 Oct;12(10):1618-26. doi: 10.1038/sj.leu.2401152. Leukemia. 1998. PMID: 9766508 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters